DCM
ALLO icon

Dupont Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Dupont Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,365
Closed -$123K – 1430
2022
Q3 		$123K Sell
11,365
-4,452
-28% -$60.5K 0.01% 977
2022
Q2 		$180K Hold
15,817
– – 0.01% 1011
2022
Q1 		$144K Sell
15,817
-1,399
-8% -$14.6K 0.01% 1184
2021
Q4 		$257K Buy
17,216
+5,528
+47% +$97.5K 0.01% 1023
2021
Q3 		$300K Sell
11,688
-1,653
-12% -$39.2K 0.01% 1071
2021
Q2 		$348K Buy
+13,341
New +$380K 0.01% 1151

Other funds holding ALLO

TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dupont Capital Management's ALLO Position: Q4 2022 in Review

Dupont Capital Management sold out of Allogene Therapeutics (ALLO) in Q4 2022, closing a stake of 11,365 shares — an estimated $123K sold.

Dupont Capital Management first reported a position in ALLO in Q2 2021 and held it in 6 quarters. The position peaked at $348K in Q2 2021. 168 funds tracked by Wall St. Rank hold ALLO as of Q4 2022.

  • Dupont Capital Management reported no remaining Allogene Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Dupont Capital Management sold 11,365 Allogene Therapeutics shares in Q4 2022, an estimated $123K.
  • Dupont Capital Management first reported a position in Allogene Therapeutics in Q2 2021 and held it in 6 quarters.
  • Dupont Capital Management's Allogene Therapeutics position peaked at $348K in Q2 2021.
  • 168 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2022.

Based on Dupont Capital Management's 13F filing for Q4 2022, filed 26 Jan 2023.